Another ongoing trial of the GCLLSG, CLL 16 (NCT05197192), will only enroll previously untreated patients with high-risk CLL: The phase 3 trial will compare VO to VO plus acalabrutinib in patients with a 17p deletion and/or TP53 mutation and/or complex karyotype. The gene discussed is TP53; the disease is B-cell chronic lymphocytic leukemia.